Key result
Intravenous tirofiban infusion reduced the frequency of postprocedural abnormal cTn-I levels compared to standard therapy in patients undergoing elective PCI.
Why the study?
Does intravenous tirofiban infusion reduce minor myocardial injury (cTn-I and cTn-T elevation) in patients undergoing elective percutaneous coronary intervention?
RCT (n=119)
Does intravenous tirofiban infusion reduce minor myocardial injury (cTn-I and cTn-T elevation) in patients undergoing elective percutaneous coronary intervention?
Glycoprotein IIb/IIIa inhibition with tirofiban significantly reduces the incidence of minor myocardial injury (troponin elevation) following elective percutaneous coronary intervention.
Answers are grounded in this paper and cite their sources.
Supports tirofiban to reduce minor myocardial injury in elective PCI; extends GP IIb/IIIa evidence to lower-risk procedures.
AIM: The aim of the study was to evaluate the effects of glycoprotein (GP) IIb/IIIa inhibition on minor myocardial injury characterized by cardiac troponin I (cTn-I) and cardiac troponin T (cTn-T) elevation after elective successful percutaneous coronary intervention (PCI). METHODS: The study consisted of 119 consecutive patients scheduled for elective coronary balloon angioplasty with or without stent implantation. Sixty-three patients (mean age 58 +/- 9.4 years) were randomized to receive standard therapy, including preprocedural aspirin, ticlopidine and intravenous heparin, and 56 patients (mean age 55 +/- 9.6 years) were randomized to additionally receive intravenous tirofiban infusion. cTn-I, cTn-T and CK-MB were measured before and immediately after the procedure, and every 6 h for the first 24 h. A total of 128 stenoses were treated with PCI. Seventy of these lesions were in the standard therapy group and 58 in the tirofiban group. RESULTS: The frequency of postprocedural abnormal cTn-I levels was significantly higher in the standard therapy group than that in the tirofiban group (37 vs. 16%; p = 0.017). Postprocedural cTn-T elevation occurred in 23% of patients in the standard therapy group and in 8% of patients in the tirofiban group (p = 0.037). The frequencies of CK-MB elevation higher than the upper limit of normal (ULN), and higher than 2 times the ULN were not significantly different between the standard therapy and tirofiban groups (12 vs. 4%, and 7 vs. 2%, respectively). CONCLUSIONS: GP IIb/IIIa inhibition may reduce the incidence of minor myocardial injury, which may also be a possible mechanism in reducing long-term cardiac events after PCI.
No takes yet. Share an insight, caveat, or question.
Ökmen et al. (2004) conducted an RCT in Elective percutaneous coronary intervention (PCI) (n=119). Tirofiban vs. Standard therapy (preprocedural aspirin, ticlopidine, and intravenous heparin) was evaluated on Postprocedural abnormal cTn-I levels (p=0.017). Intravenous tirofiban infusion reduced the frequency of postprocedural abnormal cTn-I levels compared to standard therapy in patients undergoing elective PCI.
Synapse has enriched 10 related papers. Consider them for comparative context: